IMAAVY nipocalimab-aahu has become the first therapy proven safe and effective specifically for warm autoimmune hemolytic anemia (wAIHA), Johnson & Johnson (NYSE: JNJ) announced on August 24, 2026. The U.S. Food and Drug Administration approved the medicine for adults and pediatric patients 12 years of age and older who are currently or previously treated with corticosteroids. The decision follows an earlier FDA Priority Review designation and marks a milestone for a rare, life-threatening blood disorder that has never before had a disease-specific approved therapy.
The announcement was made from Spring House, Pennsylvania, where Johnson & Johnson is headquartered for its Innovative Medicine division. Patient advocacy leader Karen Jones, President and Executive Director of wAIHA Warriors, described the emotional toll of the disease, noting that patients often cycle between feeling well and relapsing without warning. She said “our community has a treatment specifically for our disease” for the first time, capturing the significance of the approval for a long-underserved patient population.
Warm autoimmune hemolytic anemia occurs when pathogenic immunoglobulin G (IgG) autoantibodies attach to red blood cells and destroy them, causing severe anemia, profound fatigue, and an elevated risk of serious complications. Until this approval, physicians had only corticosteroids and broad immunosuppressants available — treatments that suppress the entire immune system rather than targeting the specific autoantibodies responsible for the disease.
David Kuter, M.D., D.Phil., of Massachusetts General Hospital and Harvard Medical School, who served as a study investigator, explained that the Phase 2/3 ENERGY trial showed targeting pathogenic IgG can shift the treatment paradigm for wAIHA. According to his summary of the data, more patients on IMAAVY achieved a durable hemoglobin response than those on placebo, and those gains were sustained over time rather than temporary.
IMAAVY Nipocalimab-aahu Clinical Evidence From the ENERGY Study
The FDA approval of IMAAVY nipocalimab-aahu rests on results from the pivotal, randomized, placebo-controlled Phase 2/3 ENERGY study, which enrolled 115 adults with wAIHA in an approximate 1:1:1 allocation across two nipocalimab dosing schedules and placebo. The trial’s primary endpoint, durable hemoglobin response, was defined as a hemoglobin concentration of at least 10 g/dL together with an increase from baseline of at least 2 g/dL sustained for a minimum of 28 days without rescue therapy, with criteria first met by Week 16.
At the approved dose of 30 mg/kg administered intravenously every four weeks, roughly three times as many IMAAVY nipocalimab-aahu patients reached durable hemoglobin response by Week 24 compared with placebo. Patients receiving the therapy also showed a mean hemoglobin increase of 1 g/dL as early as Week 1, with a median time to first response of 4.1 weeks versus 12.1 weeks for placebo. On the FACIT-Fatigue quality-of-life scale, IMAAVY-treated patients recorded a 3.5-point higher mean score than placebo at Week 24, reflecting a meaningful reduction in disease-related exhaustion.
Safety findings from ENERGY were consistent with the established profile of IMAAVY nipocalimab-aahu already observed in generalized myasthenia gravis. The most common adverse reactions occurring in 10% or more of wAIHA patients were peripheral edema, diarrhea, and pyrexia (fever). Full ENERGY trial results were first presented at the European Hematology Association 2026 Congress in June 2026, ahead of this regulatory decision.
About IMAAVY Nipocalimab-aahu and Its Mechanism of Action
IMAAVY nipocalimab-aahu is an immunoselective FcRn blocker engineered to bind the neonatal Fc receptor with high affinity, reducing circulating pathogenic IgG autoantibodies while preserving normal B-cell function. This mechanism distinguishes it from broad immunosuppressive therapies because it selectively interrupts the antibody recycling pathway that keeps disease-driving IgG molecules circulating in the bloodstream.
This wAIHA clearance is the second FDA approval for the medicine. IMAAVY was first approved in the United States in April 2025 for generalized myasthenia gravis in patients 12 and older who test positive for acetylcholine receptor or muscle-specific kinase antibodies. David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head at Johnson & Johnson, called the wAIHA clearance an extraordinary milestone for an underserved community, adding that the company intends to keep pursuing therapies for allo- and autoantibody-driven diseases. Nipocalimab, the molecule behind IMAAVY, is also under investigation across rheumatologic conditions, other rare autoantibody diseases, and maternal-fetal disorders mediated by alloantibodies.
Regulatory Milestones and Designations for IMAAVY Nipocalimab-aahu
Ahead of this approval, nipocalimab accumulated a series of expedited-pathway designations from U.S. and European regulators. The FDA granted Fast Track designation for wAIHA in July 2019, and Orphan Drug status for wAIHA followed in December 2019. The therapy also holds Fast Track and orphan designations across gMG, hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, Sjögren’s disease, and systemic lupus erythematosus, along with Breakthrough Therapy designations in two of those indications. Priority Review was granted for gMG in the fourth quarter of 2024 and for wAIHA in the second quarter of 2026, directly preceding this approval.
wAIHA itself remains rare: an estimated one to three new cases occur per 100,000 people annually, and roughly one in 8,000 individuals lives with the condition, according to the epidemiological data cited in the announcement. The disease affects both men and women and can occur at any age, though incidence rises after age 50. Patients with wAIHA also face heightened risk of venous thrombotic events, acute renal failure, and infection, underscoring why a targeted therapy option carries outsized clinical importance.
Patient Access and Safety Considerations for IMAAVY Nipocalimab-aahu
Johnson & Johnson has paired the approval with the IMAAVY withMe support program, which offers educational resources, a dedicated Nurse Navigator, and cost-support options regardless of a patient’s insurance type once a prescription decision is made. The company positions this infrastructure as central to translating regulatory approval into real-world patient access.
Prescribing information for IMAAVY nipocalimab-aahu carries warnings about infection risk, hypersensitivity reactions such as angioedema and anaphylaxis, and infusion-related reactions that can occur during or after treatment. Patients are advised not to receive live vaccines while on therapy, and a pregnancy safety study is monitoring outcomes for patients exposed to the drug during pregnancy. The most common side effects reported in gMG patients were respiratory tract infection, peripheral edema, and muscle spasms, while wAIHA patients most often reported peripheral edema, diarrhea, and fever. The medicine is supplied in 300 mg/1.62 mL and 1,200 mg/6.5 mL single-dose vials for intravenous administration, and its legal manufacturer is Janssen Biotech, Inc.
